NAOGEN PHARMA S.A.S, a French pharmaceutical manufacturing and operating laboratory based in Saint-Herblain, has been producing a radiopharmaceutical drug that it has been marketing since 2024 following the receipt of its Marketing Authorization (MA) in 2023. Founded in 2016 by Jean-François Chatal, a pioneer in nuclear medicine, in the wake of academic research and development work by GIP Arronax and the company Lemer Pax. The success of Naogen Pharma is the result of many years of intense R&D efforts and investments supported by the State, the Regional Council, and the competitiveness clusters, Atlanpole and Atlanpole Biotherapy.